In contrast, when the number of metastases exceeds 3, the tumor burden is heavier, VEGF secretion is excessive, and the vascular network is complex—making it difficult for the drug to act sufficiently and reducing treatment sensitivity. This evidence concerns the gene VEGFA and neoplasm.